| Stereochemistry | ABSOLUTE |
| Molecular Formula | C14H12ClN3O2 |
| Molecular Weight | 289.717 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]1(CCCN1)C2=NC3=C(OC4=C3C=C(Cl)C=C4)C(=O)N2
InChI
InChIKey=JJWLXRKVUJDJKG-VIFPVBQESA-N
InChI=1S/C14H12ClN3O2/c15-7-3-4-10-8(6-7)11-12(20-10)14(19)18-13(17-11)9-2-1-5-16-9/h3-4,6,9,16H,1-2,5H2,(H,17,18,19)/t9-/m0/s1
| Molecular Formula | C14H12ClN3O2 |
| Molecular Weight | 289.717 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
BMS-863233, also known as XL413, is a potent and selective cell division cycle 7 (CDC7) kinase inhibitor with potential antineoplastic activity. BMS-863233 binds to and inhibits the activity of CDC7, which may result in the inhibition of DNA replication and mitosis, the induction of tumor cell apoptosis, and the inhibition of tumor cell proliferation in CDC7-overexpressing tumor cells. CDC7, a serine-threonine kinase overexpressed in a variety of tumor cell types, plays an essential role in the initiation of DNA replication by activating origins of replication.
Originator
Approval Year
Sourcing
PubMed
Patents
Sample Use Guides
|
|
SALT/SOLVATE -> PARENT | |||
|
|
TARGET -> INHIBITOR |
|
Showing 1 to 2 of 2 entries
